A phase 1b study of RXDX-105, a VEGFR-sparing potent RET inhibitor, in RETi-naïve patients with RET fusion-positive NSCLC
Year: 2017
Type: article
Study design: Clinical Trial
Source: Annals of Oncology
Institutions: Memorial Sloan Kettering Cancer Center, Georgetown University Medical Center, MedStar Georgetown University Hospital, University of Colorado Anschutz, Seattle Cancer Care Alliance, University of Washington, City Of Hope National Medical Center, City of Hope, University of California San Diego, Moores Cancer Center, Yonsei University, Yonsei Cancer Hospital, Ignyta (United States), Samsung Medical Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2761551369